Open Label Trial to Assess Iressa in Prostate Cancer Patients

Phase 2CompletedNCT00635856

AstraZeneca100 enrolled

Overview

A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

100

Conditions

Prostate Cancer

Interventions

GefitinibDRUG

Iressa

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Prostate cancer diagnosis * no evidence of metastasis * Age 18 or older Exclusion Criteria: * Prior chemotherapy for recurrent prostate cancer * Radiotherapy completed within 28 days of starting the study * Incomplete healing from prior cancer or other major surgery

Outcomes

Primary Outcomes

Serum Prostate Specific Antigen

Time frame: Monthly

Secondary Outcomes

Duration of PSA decline

Time frame: Monthly

Safety variables

Time frame: Monthly

Time to Progression

Time frame: Every 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.